Published in J Immunol on April 15, 1988
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J (1991) 8.31
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci U S A (1989) 5.07
Tumor necrosis factor and interferon-gamma induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol (1989) 2.72
Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med (1988) 2.07
Interindividual concordance of methylation profiles in human genes for tumor necrosis factors alpha and beta. Proc Natl Acad Sci U S A (1990) 2.03
Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am J Pathol (1991) 1.88
Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. J Exp Med (1989) 1.62
Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Clin Exp Immunol (1991) 1.55
Transcriptional control of the TNF gene. Curr Dir Autoimmun (2010) 1.32
Lymphotoxin activation by human T-cell leukemia virus type I-infected cell lines: role for NF-kappa B. J Virol (1990) 1.30
Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci U S A (1994) 1.28
Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. J Exp Med (1989) 1.26
Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin Exp Immunol (2000) 1.13
DNA methylation profiles in the human genes for tumor necrosis factors alpha and beta in subpopulations of leukocytes and in leukemias. Proc Natl Acad Sci U S A (1991) 1.01
In vitro production of tumour necrosis factor and prostaglandin E2 by peripheral blood mononuclear cells from tuberculosis patients. Clin Exp Immunol (1990) 1.01
Epigenetic control of cytokine gene expression: regulation of the TNF/LT locus and T helper cell differentiation. Adv Immunol (2013) 0.94
Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2. Immunology (1989) 0.94
Francisella tularensis-induced in vitro gamma interferon, tumor necrosis factor alpha, and interleukin 2 responses appear within 2 weeks of tularemia vaccination in human beings. J Clin Microbiol (1991) 0.94
Immunohistochemical studies of intrahepatic tumour necrosis factor alpha in chronic liver disease. J Clin Pathol (1990) 0.90
Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis. Clin Exp Immunol (1990) 0.85
Production of tumour necrosis factor by mastocytoma P815 cells. Immunology (1990) 0.82
Lymphotoxin organizes contributions to host defense and metabolic illness from innate lymphoid cells. Cytokine Growth Factor Rev (2013) 0.78
Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients. Clin Exp Immunol (1994) 0.77
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med (2001) 9.53
Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood (2000) 9.24
Evidence for circulating bone marrow-derived endothelial cells. Blood (1998) 6.15
Ontogeny of the haemopoietic system: yolk sac origin of in vivo and in vitro colony forming cells in the developing mouse embryo. Br J Haematol (1970) 4.32
Experimental studies on the development of the thymus. J Exp Med (1967) 3.94
Comparative study of diagnostic procedures for congenital cytomegalovirus infection. Pediatrics (1980) 3.53
Production of Shiga-like toxin by Escherichia coli. J Infect Dis (1986) 3.53
Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood (1980) 3.51
Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J Exp Med (1976) 3.49
Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A (1997) 3.30
Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med (2001) 3.25
A transplantable myelomonocytic leukemia in BALB-c mice: cytology, karyotype, and muramidase content. J Natl Cancer Inst (1969) 3.06
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A (1985) 3.02
Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood (2001) 3.01
Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J Exp Med (1996) 2.71
Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Differentiation (1997) 2.58
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol (1993) 2.47
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med (1988) 2.40
Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine (1995) 2.34
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Colony formation in vitro by myelomonocytic leukemic cells. J Natl Cancer Inst (1969) 2.21
Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med (1987) 2.17
Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA (1998) 2.16
Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med (1997) 2.12
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest (2000) 2.08
Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J Clin Invest (2000) 2.05
Long-term in vitro culture of murine mast cells. I. Description of a growth factor-dependent culture technique. J Immunol (1981) 1.99
Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood (1995) 1.94
Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood (1994) 1.90
Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A (2001) 1.90
Growth of B-lymphocytes clones in semisolid culture is mitogen dependent. J Exp Med (1976) 1.86
Specific expression of the human cellular fps/fes-encoded protein NCP92 in normal and leukemic myeloid cells. Proc Natl Acad Sci U S A (1985) 1.83
Long-term in vitro culture of murine mast cells. II. Purification of a mast cell growth factor and its dissociation from TCGF. J Immunol (1981) 1.71
Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci (1997) 1.71
The fate of fetal and adult B-cell progenitors grafted into immunodeficient CBA/N mice. J Exp Med (1979) 1.68
Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res (1997) 1.68
Regulation of B-lymphocyte clonal proliferation by stimulatory and inhibitory macrophage-derived factors. J Exp Med (1977) 1.67
Chromosome marker studies on the development of the haemopoietic system in the chick embryo. Nature (1965) 1.66
In vitro colony formation by normal and leukemic human hematopoietic cells: characterization of the colony-forming cells. J Natl Cancer Inst (1973) 1.65
Agar culture studies in 127 cases of untreated acute leukemia: the prognostic value of reclassification of leukemia according to in vitro growth characteristics. Blood (1974) 1.64
Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor cell proliferation. Proc Natl Acad Sci U S A (1979) 1.63
Differentiation of mouse bone marrow precursor cells into neutrophil granulocytes by an activity separation from WEHI-3 cell-conditioned medium. Differentiation (1978) 1.61
Limitation of excessive myelopoiesis by the intrinsic modulation of macrophage-derived prostaglandin E. Science (1978) 1.60
Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. Blood (1993) 1.58
Role of stem cell migration in initiation of mouse foetal liver haemopoiesis. Nature (1975) 1.56
Interactions among colony-stimulating factors, IL-1 beta, IL-6, and kit-ligand in the regulation of primitive murine hematopoietic cells. Exp Hematol (1992) 1.56
Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood (1997) 1.52
Regulation of macrophage and granulocyte proliferation. Specificities of prostaglandin E and lactoferrin. J Exp Med (1979) 1.51
Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med (1982) 1.50
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia (2005) 1.48
Embryonic origin of the mouse macrophage. Blood (1972) 1.47
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia (2003) 1.47
Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. Exp Hematol (2001) 1.45
Induction of antibody-dependent and nonspecific tumor killing in human monocytic leukemia cells by nonlymphocyte factors and phorbol ester. Cell Immunol (1982) 1.44
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia (2012) 1.44
Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency. J Clin Immunol (1984) 1.44
Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med (1998) 1.43
Experimental studies on the development of the bursa of Fabricius. Dev Biol (1966) 1.41
Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol (1995) 1.39
Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med (1985) 1.37
Regulation of megakaryopoiesis in long-term murine bone marrow cultures. Blood (1978) 1.37
Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2. J Clin Immunol (1983) 1.36
In vitro colony formation by normal and leukemic human hematopoietic cells: interaction between colony-forming and colony-stimulating cells. J Natl Cancer Inst (1973) 1.34
Purification and characterisation of the in vitro colony forming cell in monkey hemopoietic tissue. J Cell Physiol (1972) 1.32
Inhibition of human erythropoietic colony formation in culture by treatment with Ia antisera. J Exp Med (1978) 1.32
Transgenic expression of PML/RARalpha impairs myelopoiesis. Proc Natl Acad Sci U S A (1996) 1.31
Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood (1981) 1.28
Consequences of exclusive expression in vivo of Kit-ligand lacking the major proteolytic cleavage site. Proc Natl Acad Sci U S A (1998) 1.28
Modulation of hemopoiesis by prostaglandins. Exp Hematol (1977) 1.27
Cell-free granulocyte colony inhibiting activity derived from human polymorphonuclear neutrophils. Exp Hematol (1977) 1.26
Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood (2000) 1.26
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol (1999) 1.25
A soluble form of human Delta-like-1 inhibits differentiation of hematopoietic progenitor cells. Blood (2000) 1.23
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia (2012) 1.23
Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood (1996) 1.21
Density distribution analysis of in vivo and in vitro colony forming cells in bone marrow. J Cell Physiol (1970) 1.20
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia (2013) 1.20
Aplastic anemia: presence in human bone marrow of cells that suppress myelopoiesis. Proc Natl Acad Sci U S A (1976) 1.20
Role of cyclic nucleotides in the proliferation of committed granulocyte-macrophage progenitor cells. Cancer Res (1977) 1.19
OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells. J Immunol (1983) 1.19
Rapid increase in desflurane concentration is associated with greater transient cardiovascular stimulation than with rapid increase in isoflurane concentration in humans. Anesthesiology (1994) 1.18
Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther (2009) 1.18
Long-term in vitro culture of murine mast cells. III. Discrimination of mast cells growth factor and granulocyte-CSF. J Immunol (1982) 1.17
Two dimensional cell separation: comparison of embryonic and adult haemopoietic stem cells. Nature (1970) 1.16
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia (2003) 1.16
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol (2004) 1.15
High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst (1997) 1.15
Effect of chloramphenicol and thiamphenicol on the in vitro colony-forming cell. Blood (1974) 1.14
Maintenance of hemopoietic stem cells and production of differentiated progeny in allogeneic and semiallogeneic bone marrow chimeras in vitro. J Exp Med (1977) 1.14
Pluripoietin alpha: a second human hematopoietic colony-stimulating factor produced by the human bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A (1986) 1.14
Synergism among interleukin 1, interleukin 3, and interleukin 5 in the production of eosinophils from primitive hemopoietic stem cells. J Immunol (1988) 1.14
Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nat Med (2000) 1.13
Physical separation of colony stimulating cells from in vitro colony forming cells in hemopoietic tissue. J Cell Physiol (1972) 1.13